MCID: CHL033
MIFTS: 15

Childhood Malignant Schwannoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Childhood Malignant Schwannoma

MalaCards integrated aliases for Childhood Malignant Schwannoma:

Name: Childhood Malignant Schwannoma 12 15
Childhood Neurofibrosarcoma 73
Pediatric Mpnst 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7732
NCIt 50 C8094
UMLS 73 C0279987

Summaries for Childhood Malignant Schwannoma

MalaCards based summary : Childhood Malignant Schwannoma, is also known as childhood neurofibrosarcoma. An important gene associated with Childhood Malignant Schwannoma is BIRC5 (Baculoviral IAP Repeat Containing 5). The drugs Doxorubicin and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include bone.

Related Diseases for Childhood Malignant Schwannoma

Symptoms & Phenotypes for Childhood Malignant Schwannoma

Drugs & Therapeutics for Childhood Malignant Schwannoma

Drugs for Childhood Malignant Schwannoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Not Applicable 51-75-2 4033
3
Ifosfamide Approved Phase 3,Phase 2,Not Applicable 3778-73-2 3690
4
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
5
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
6
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
7
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
9
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
10
Epirubicin Approved Phase 3 56420-45-2 41867
11
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
12
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
13
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
16
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
17
Isophosphamide mustard Phase 3,Phase 2,Not Applicable 0
18 Alkylating Agents Phase 3,Phase 2,Not Applicable
19 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
20 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
21 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
22 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Not Applicable
23 Imatinib Mesylate Phase 2, Phase 3 220127-57-1 123596
24 Nucleic Acid Synthesis Inhibitors Phase 3
25 Etoposide phosphate Phase 3,Phase 2
26 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
27 Anti-Infective Agents Phase 3,Phase 2,Phase 1
28 Protein Kinase Inhibitors Phase 2, Phase 3
29 Antirheumatic Agents Phase 3,Phase 1
30 Antimitotic Agents Phase 3,Phase 2,Phase 1
31 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
32 Antimetabolites Phase 3,Phase 2,Phase 1
33 Antiviral Agents Phase 3,Phase 2,Phase 1
34 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
35
Histamine Phosphate Phase 3 51-74-1 65513
36 Serotonin Agents Phase 3
37 Serotonin Antagonists Phase 3
38 Gastrointestinal Agents Phase 3
39 Neurotransmitter Agents Phase 3
40 Histamine Antagonists Phase 3
41 Histamine H1 Antagonists Phase 3
42 Dermatologic Agents Phase 3
43 Anti-Allergic Agents Phase 3
44 Antipruritics Phase 3
45
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
46
Lenograstim Approved, Investigational Phase 2 135968-09-1
47
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
48
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
49
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
50
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
4 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
5 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
6 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
7 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
8 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
9 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
10 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
11 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
12 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
13 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
14 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
15 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
16 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2 Pembrolizumab
17 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
18 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02986919 Phase 2 CPI-0610
19 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2 Tazemetostat
20 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
21 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
22 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
23 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
24 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
25 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Active, not recruiting NCT01661283 Phase 2 everolimus;bevacizumab
26 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Active, not recruiting NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
27 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
28 Trial of Dasatinib in Advanced Sarcomas Active, not recruiting NCT00464620 Phase 2 Dasatinib
29 SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the Dual mTOR Kinase Inhibitor Vistusertib (AZD2014) for Patients With Malignant Peripheral Nerve Sheath Tumors Not yet recruiting NCT03433183 Phase 2 Selumetinib;Vistusertib
30 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
31 Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients Completed NCT01169584 Phase 1 Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
32 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
33 HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors Completed NCT00931931 Phase 1
34 Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Completed NCT00450736 Phase 1 celecoxib
35 Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery Recruiting NCT02700230 Phase 1
36 Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Recruiting NCT02211768 Phase 1
37 Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Recruiting NCT03009201 Phase 1 Doxorubicin;Ribociclib
38 A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma Active, not recruiting NCT02601937 Phase 1 Tazemetostat
39 Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis Unknown status NCT01777451
40 Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients Unknown status NCT01218139
41 Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs Unknown status NCT01218152
42 Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas Completed NCT01567046
43 Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma Completed NCT00003793
44 Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors Recruiting NCT03141021
45 Natural History Study of Patients With Neurofibromatosis Type I Recruiting NCT00924196
46 PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma Active, not recruiting NCT00346125 Not Applicable doxorubicin hydrochloride;ifosfamide;pegylated liposomal doxorubicin hydrochloride
47 Proton Radiation Therapy for Spinal Tumors Withdrawn NCT01567787 Not Applicable
48 Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma Withdrawn NCT00334984 Not Applicable glutamine

Search NIH Clinical Center for Childhood Malignant Schwannoma

Genetic Tests for Childhood Malignant Schwannoma

Anatomical Context for Childhood Malignant Schwannoma

MalaCards organs/tissues related to Childhood Malignant Schwannoma:

41
Bone

Publications for Childhood Malignant Schwannoma

Variations for Childhood Malignant Schwannoma

Expression for Childhood Malignant Schwannoma

Search GEO for disease gene expression data for Childhood Malignant Schwannoma.

Pathways for Childhood Malignant Schwannoma

GO Terms for Childhood Malignant Schwannoma

Sources for Childhood Malignant Schwannoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....